Modality
Gene Editing
MOA
CDK4/6i
Target
CD3
Pathway
Innate Imm
ThymomaGastric CaPompe
Development Pipeline
Preclinical
Oct 2018
→ Nov 2029
PreclinicalCurrent
NCT04757932
929 pts·Thymoma
2018-10→2029-11·Recruiting
929 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-11-053.6y awayInterim· Thymoma
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Preclinical
Recruit…
Catalysts
Interim
2029-11-05 · 3.6y away
Thymoma
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04757932 | Preclinical | Thymoma | Recruiting | 929 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R | |
| Miriglumide | Alnylam | Phase 3 | CD3 |